191739-36-3

Basic information

• Product Name: 1,2,4-Piperazinetricarboxylic acid, 1,4-bis(phenylmethyl) ester
• CAS NO: 191739-36-3
• Molecular Formula: C21H22N2O6
• Molecular Weight: 398.415
• Mol File: 191739-36-3.mol

Chemical Properties

• CAS DataBase Reference: 1,2,4-Piperazinetricarboxylic acid, 1,4-bis(phenylmethyl) ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2,4-Piperazinetricarboxylic acid, 1,4-bis(phenylmethyl) ester(191739-36-3)
• EPA Substance Registry System: 1,2,4-Piperazinetricarboxylic acid, 1,4-bis(phenylmethyl) ester(191739-36-3)

Safety Data

• Hazardous Substances Data: 191739-36-3(Hazardous Substances Data)

Usage

Common use

Reagent in organic synthesis and pharmaceutical research

Potential medicinal properties

a. Anti-inflammatory effects
b. Analgesic effects

Investigated for treatment of

a. Cancer
b. Neurodegenerative disorders

Potential application

Corrosion inhibitor in industrial processes

Interest to researchers and professionals

Various scientific and industrial applications

Upstream product

• 3022-15-9 piperazine-2-carboxylic acid dihydrochloride 
• 501-53-1 benzyl chloroformate 
• 98-97-5 2-pyrazylcarboxylic acid 
• 2762-32-5 piperazine-2-carboxylic acid 

Downstream Products

• 385765-07-1 C₄₁H₃₈N₄O₉ 
• 191739-39-6 benzyl 3-oxotetrahydro-1H-oxazolo[3,4-a]pyrazine-7(3H)-carboxylate 
• 161894-56-0 dibenzyl 2-(hydroxymethyl)piperazine-1,4-dicarboxylate 

Relevant articles and documents

QUINOLINE DERIVATIVES AS SMO INHIBITORS

Disclosed are quinoline derivatives as hedgehog pathway inhibitors, especially as SMO inhibitors. Compounds of the present invention can be used in treating diseases relating to hedgehog pathway including cancer.

NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF

Disclosed are novel piperazine derivatives that act as agonists of the α7 nAChR. Also disclosed are phannaceutical compositions, methods of treating inflammatory conditions, methods of treating CNS disorders, methods for inhibiting cytokine release from mammalian cells and methods for the preparation of the novel compounds.

An orthogonal protection strategy for the synthesis of 2-substituted piperazines

Tetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-ones are readily prepared from the bis-carbamate protected piperazine-2-carboxylic acids and serve as orthogonally protected piperazines from which a variety of 2-substituted piperazines can be prepared. Sodium benzylate and sodium phenoxides react at the C-5 carbon of the oxazolidinone to yield 2-(benzyloxymethyl)piperazines and 2-(phenoxymethyl)piperazines, respectively. The tetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-ones also provide convenient scaffolds from which 2-benzyl- and 2-phenethylpiperazines are prepared.

BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS

Compounds of formula (I) are useful in the treatment of vanilloid-receptor-meditated diseases, such as inflammatory or neuropathic pain and diseases involving sensory nerve function such as asthma, rheumatoid arthritis, osteoarthritis, inflammatory bowel disorders, urinary incontinence, migraine and psoriasis.

OXAZOLIDINONE ANTIBACTERIAL AGENT WITH TRICYCLIC SUBSTITUENTS

This invention provides novel oxazolidinone derivatives represented by chemical formula (I), or pharmaceutically acceptable salts thereof: wherein X is NR1, CR2R3, O, S, SO, or SO2; and Z is NR4, S, SO, SO2 or O. The compounds are useful antimicrobial age

Cyclic gmp-specific phosphodiesterase inhibitors

Compounds of general structural formula (I) and use of the compounds and salts and solvates thereof, as therapeutic agents.

TREATMENT OF MALARIA WITH FARNESYL PROTEIN TRANSFERASE INHIBITORS

Disclosed is a method of treating Malaria comprising administering an effective amount of an FPT inhibitor to a patient in need of such treatment alone or in combination with an additional antimalarial agent andlor agent for reversing antimalarial resistance. Also disclosed are novel Farnesyl Protein Transferase inhibitors.

Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors

Disclosed is a method of treating and or preventing infections of Trypanosoma brucei by administering to a patient, in need of such treatment, an effective amount of a Farnesyl Protein Transferase Inhibitor alone or in combination with an additional anti-Trypanosoma brucei agent and/or an anti-Trypanosoma brucei resistance reversing agent.

Farnesyl protein transferase inhibitors

Disclosed are compounds of the formula: wherein R13represents an imidazole ring; R14represents a carbamate, urea, amide or sulfonamide group; R8represents H when the alkyl chain between the amide group and the R13imidazole group is substituted, or R8represents a substituent such as arylalkyl, heteroarylalkyl or cycloalkyl; and the remaining substituents are as defined herein. Also disclosed are compounds wherein R8is H, and the alkyl chain between the amide group and the R13imidazole group is unsubstituted. Also disclosed is a method of treating cancer and a method of inhibiting farnesyl protein transferase using the disclosed compounds.

Oxazolidinone antibacterial agent with tricyclic substituents

This invention provides novel oxazolidinone derivatives represented by chemical Formula (I), or pharmaceutically acceptable salts thereof: STR1 wherein X is NR1, CR2 R3, O, S, SO, or SO2 ; and Z is NR4/sub